HR Execs on the Move

Alliance Health

www.alliancehealth.com

 
Alliance Health is an innovative technology company whose mission is to improve health outcomes, lower costs and foster a more consumer-centric healthcare industry. We own and operate the internet`s largest group of condition-specific social communities serving over 1.5 million registered members across a broad set of chronic health conditions. Each site leverages social and mobile elements to empower patients and caregivers with connections to supportive peers, personalized information, and relevant products and services. We also offer access to affordable prescription medications, either home-delivered, or through our pharmacy network.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Cosmo Bio USA

Cosmo Bio USA is a company that provides quality life science products from leading Japanese manufacturers to laboratories, research institutes, life science education and testing organizations throughout North America.

Independent Living Inc. Pediatric Therapy Tampa FL

FREE developmental screening! Tampa, St. Petersburg, Wesley Chapel clinic and school based pediatric therapy services. Physical, Occupational, Speech, Applied Behavioral Analysis

Fifty 50 Pharmacy

Fifty 50 Pharmacy is a Carrollton, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.